Doxorubicin and Thermal Ablation: Do Chemo Drugs Survive the Heat?
"A new study investigates if the chemotherapy drug doxorubicin remains effective after thermal ablation, a common cancer treatment."
For individuals battling liver cancer, combined transarterial chemoembolization (TACE) and percutaneous thermal ablation has emerged as a powerful treatment option. TACE delivers chemotherapy directly to the tumor site, while thermal ablation uses heat to destroy cancerous cells. The combined approach aims to maximize the destruction of tumors while minimizing side effects. But a crucial question remains: does the chemotherapeutic drug, specifically doxorubicin (DOX), survive the extreme heat of thermal ablation?
The effectiveness of TACE followed by thermal ablation hinges on whether the chemotherapy drug can withstand the heat. If the drug degrades during the ablation process, the potential benefits of the combined approach may be limited. Understanding the thermal effects on locally delivered chemotherapeutic drugs is therefore essential for optimizing cancer treatment strategies.
To investigate this critical question, a new ex vivo study was undertaken to test the hypothesis that doxorubicin chemotherapy can survive thermal ablative heating. This research provides valuable insights into the stability of doxorubicin under thermal stress, potentially impacting how combined cancer treatments are planned and executed.
Clinical Reach of Thermal Ablation
A December 1, 2024 study evaluated the safety and efficacy of radiofrequency ablation (RFA) and microwave ablation (MWA) for patients with stage I non-small cell lung cancer (NSCLC). A separate meta-analysis examined thermal ablation plus chemotherapy compared with chemotherapy alone in lung cancer. Thermal ablation modalities, including high-intensity focused ultrasound, RFA, MWA, and laser interstitial thermal therapy, can create confined zones of tissue destruction, potentially producing fewer complications than conventional cancer therapies.
Methods and Constraints
Thermal ablation applies thermal energy to tissue to produce necrosis and tumor destruction. Major modalities include microwave ablation, radiofrequency ablation, cryoablation, high-intensity focused ultrasound, and laser interstitial thermal therapy, with each having distinct strengths, weaknesses, and potential complications. Reviews also identify persistent limitations involving procedure monitoring, follow-up imaging, tumor stage, lesion characteristics, and context-specific safety and efficacy.
From Hyperthermia to Ablation
The history of tumor ablation includes heating, freezing, radiation, chemotherapy, tumor blood-supply occlusion, direct injection of caustic agents, and combinations of these techniques. Effective local or regional hyperthermic cancer therapy can involve longer heating at 41-45°C or shorter treatment at higher temperatures. Minimally invasive thermal techniques such as laser ablation gained popularity in recent decades as alternatives to surgery for focal tumor lesions.
Doxorubicin's Fate Under Fire: What the Study Revealed
The study, published in Diagnostic and Interventional Radiology, directly challenged the initial assumption that doxorubicin survives thermal ablation unscathed. Researchers Joseph D. Morrison, Collin K. Schlager, Amanda E. Lee, Richard B. van Breemen, and Ron C. Gaba designed an experiment to mimic the conditions of combined TACE and thermal ablation outside of a living organism.
- Unexpected Results: Contrary to the initial hypothesis, the study found that tissue doxorubicin concentration progressively decreased with increasing ablation time.
- Quantifiable Degradation: Longer exposure to microwave ablation led to a significant reduction in the amount of doxorubicin present in the tissue.
- Statistical Significance: Differences in tissue doxorubicin levels between unablated tissue and MWA groups were statistically significant (P < 0.001).
Drug Stability and Safer Ablation
A study of chemotherapy-induced tumor dormancy reports that doxorubicin was examined in forced-degradation models involving hydrolysis, peroxide oxidation, dry heat at 80°C for short durations, photolysis, and microwave irradiation. Separate recent work has focused on protective heat and cold shields for tumors near the spinal cord, cauda equina, peripheral nerves, and visceral organs. Thermal ablation is also being evaluated in low-resource settings, where devices have become more portable, user-friendly, and affordable over the past decade.
Limits of Heat and Drug Survival
An ex vivo study explicitly tested whether doxorubicin survives thermal-ablative heating in a combined transarterial chemoembolization and thermal-ablation model. The experiment used three fresh porcine psoas major muscle samples, each measuring 15×10×3 cm, submerged for 24 hours in an aqueous doxorubicin solution at 60 µg/mL and 0.1 M to passively saturate the tissue. Other reported limitations include the difficult adoption of newer electromagnetic-navigation guidance methods for lung-cancer ablation and the need to account for procedural precision and surrounding anatomy.
Anatomical Versus Routine Ablation
In a propensity-score-matched comparison for hepatocellular carcinoma tumors no larger than 50 mm, anatomical thermal ablation produced higher reported progression-free survival than routine thermal ablation. The cumulative 1-, 2-, and 3-year progression-free survival rates were 93.4%, 82.7%, and 79.0% for anatomical ablation, compared with 74.2%, 56.9%, and 51.6% for routine ablation. The reported difference was statistically significant, with p = 0.001.
Implications for Cancer Treatment: What Does This Mean for Patients?
The study's findings raise important questions about the optimal sequencing and delivery of combined TACE and thermal ablation. If thermal ablation reduces doxorubicin concentration, clinicians may need to adjust treatment protocols to ensure sufficient drug exposure to cancer cells. This could involve:
Faster Ablation and Immune Effects
Microwave ablation uses thermal energy to target and destroy tumors and operates at higher frequencies than radiofrequency ablation. According to the cited review, this enables faster ablation and larger treatment areas than other ablation methods. Microwave ablation has also been reported to activate immune responses in addition to directly destroying tumor tissue.
Options for Medically Frail Patients
A reported case describes long-term disease-free survival after repeated thermal ablation for metastatic colon cancer in an elderly patient. The patient had become unfit for further chemotherapy and conventional surgery, illustrating how treatment options may be limited by severe comorbidities or poor performance status. A separate study compares thermal ablation with repeat hepatic resection for recurrent hepatocellular carcinoma after initial liver resection, addressing an uncertain therapeutic choice.
<ul> <li><b>Adjusting drug dosages:</b> Clinicians might consider increasing the initial dose of doxorubicin during TACE to compensate for potential degradation during ablation.</li> <li><b>Optimizing ablation techniques:</b> Exploring alternative ablation methods or adjusting ablation parameters (e.g., duration, power) to minimize heat-induced drug degradation could be beneficial.</li> <li><b>Exploring alternative drugs:</b> Researching alternative chemotherapeutic agents that are more resistant to thermal degradation may offer a more effective combined treatment strategy.</li> </ul>
While this ex vivo study provides valuable insights, further research is needed to confirm these findings in living organisms. In vivo studies can account for factors such as blood flow and drug metabolism, which could influence the degradation of doxorubicin during thermal ablation. Further research may also be warranted in an in vivo animal model system to assess whether the effects are retained in living systems, and whether intraparenchymal DOX concentrations remain at cytotoxic levels following thermal ablation after delivery at standard therapeutic dosing. Despite these limitations, this research highlights the importance of understanding the interplay between chemotherapy and thermal ablation to optimize cancer treatment outcomes.